
MUSTANG BIO, INC. — Investor Relations & Filings
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-05-05 | English | |
| 8-K - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-04-17 | English | |
| Major Shareholding Notification 2026 | 2026-01-05 | English | |
| Director's Dealing 2026 | 2026-01-05 | English | |
| OWNERSHIP DOCUMENT | 2025-12-30 | English | |
| OWNERSHIP DOCUMENT | 2025-12-30 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 41519352 | 10-Q - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-05-05 | English | ||
| 34661932 | 8-K - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-04-17 | English | ||
| 12973079 | Major Shareholding Notification 2026 | 2026-01-05 | English | ||
| 12973078 | Director's Dealing 2026 | 2026-01-05 | English | ||
|
2025
11 filings
| |||||
| 12973080 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973081 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973082 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973084 | 8-K | 2025-12-23 | English | ||
| 12973083 | DEF 14A | 2025-12-03 | English | ||
| 12973085 | 10-Q | 2025-11-07 | English | ||
| 12973086 | Major Shareholding Notification 2025 | 2025-10-01 | English | ||
| 12973089 | Director's Dealing 2025 | 2025-10-01 | English | ||
| 12973087 | 424B5 | 2025-09-05 | English | ||
| 12973088 | Major Shareholding Notification 2025 | 2025-08-12 | English | ||
| 12973090 | 10-Q | 2025-08-08 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Cellectar Biosciences, Inc.
Clinical-stage biopharma developing targeted cancer treatme…
|
CLRB | US | Manufacturing |
|
Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunot…
|
ALCLS | FR | Manufacturing |
|
Cellid Co., Ltd.
Develops immunotherapeutic vaccines for cancer and infectio…
|
299660 | KR | Manufacturing |
|
Cellromax Science Co., Ltd.
Researches and develops health foods, derma-cosmetics, and …
|
471820 | KR | Manufacturing |
|
CellSeed Inc.
Develops and commercializes cell sheet engineering for rege…
|
7776 | JP | Manufacturing |
|
Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmun…
|
068270 | KR | Manufacturing |
|
Celltrion Pharm Inc.
Manufactures and supplies chemical pharmaceuticals and bios…
|
068760 | KR | Manufacturing |
|
CELLUMED CO., LTD.
Develops and manufactures medical devices, tissue grafts, a…
|
049180 | KR | Manufacturing |
|
Celon Pharma S.A.
An integrated pharmaceutical company researching and manufa…
|
CLN | PL | Manufacturing |
|
Celularity Inc
Develops allogeneic cell therapies and biomaterials from th…
|
CELU | US | Manufacturing |
MUSTANG BIO, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35167/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35167 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35167 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35167 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35167}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MUSTANG BIO, INC. (id: 35167)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.